Gain Therapeutics, Inc.
GANX
$2.12
-$0.05-2.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -23.81% | -20.42% | -17.81% | 28.66% | -12.85% |
| Total Depreciation and Amortization | -4.12% | 63.44% | 12.50% | -3.13% | 14.12% |
| Total Amortization of Deferred Charges | 9.09% | 8.33% | 0.00% | 18.18% | -8.33% |
| Total Other Non-Cash Items | 19.83% | -54.79% | 50.30% | -9.23% | 5,554.64% |
| Change in Net Operating Assets | 42.25% | 15.94% | 92.95% | -148.37% | -61.90% |
| Cash from Operations | -23.71% | -33.69% | 18.92% | 11.42% | -6.55% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -14.86% | -9.65% | -8.23% | -9.50% | 3.06% |
| Issuance of Common Stock | -82.23% | 609.72% | 796.04% | -75.24% | 1,432.17% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -83.13% | 615.63% | 769.64% | -75.42% | 1,744.10% |
| Foreign Exchange rate Adjustments | -77.53% | 120.35% | -98.25% | 1,885.50% | 124.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -226.91% | 822.21% | 143.26% | -137.68% | -13.74% |